Abstract Body

The COVID-19 pandemic is one of the greatest challenges that humankind has faced in generations. It has already cost more than five million lives globally, sickened over 300 million people around the world, upended countless livelihoods, and caused substantial economic loss. Despite advances in the development and rollout of vaccines as well as in the clinical management of patients with COVID-19, the end of the worst public-health crisis in a century is not yet in sight as new variants that decrease the effectiveness of the public health interventions and vaccines continue to emerge. Since the beginning of the pandemic there have been multiple SARS-CoV-2 variants across the world. The early Covid-19 pandemic was dominated by the D614G mutation, which was more transmissible. Over the past two years, several more variants have been identified with five becoming rapidly dominant within their countries and have raised concerns, including: Alpha (B.1.1.7 / VOC-202012/01), Beta (501Y.V2 / B.1.351), Gamma (P.1 / B.1.1.28.1), Delta (B.1.617.2) and Omicron (B.1.1.529). This presentation reflects on the identification, through genomic surveillance, and public health response to variants of concern in South Africa with a particular focus on the Beta and Omicron variants that were first identified in the country. South Africa has experienced four distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, while the second and third waves were driven by the Beta and Delta variants, respectively. The most recent wave was dominated by the Omicron variant. In November 2021, genomic surveillance teams in South Africa and Botswana detected a new SARS-CoV-2 variant associated with a rapid resurgence of infections in Gauteng Province, South Africa. Within three days of the first genome being uploaded, it was designated a variant of concern (Omicron) by the World Health Organization and, within three weeks, had been identified in 87 countries. The Omicron variant is exceptional for carrying over 30 mutations in the spike glycoprotein, predicted to influence antibody neutralization and spike function. The genomic profile, early transmission and rapid spread of Omicron will be highlighted.